Study of efficacy of oral ivermectin in comparison to commonly used topical antiscabetic drugs gamma benzene hexachloride and permethrin

Suman Kanwar*, Sunil K. Mathur, Sanjay Sankhla

INTRODUCTION

Scabies is a neglected parasitic disease that is a major public health problem in many resource-poor regions. Scabies is an infectious disease, contagious in nature and caused by Sarcoptes scabiei (it has got another name acarus) is transmitted readily, often throughout an entire household, by prolonged skin-to-skin contact with an infected person. The objective was to know the efficacy of oral ivermectin in the treatment of scabies infection in comparison to commonly used topical antiscabetic drugs gamma benzene hexachloride and permethrin.

Methods: Using prospective, longitudinal, comparative randomized design, study was conducted for a period of one year in 299 patients, in the age group of 5 to 60 years, belonging to both sexes, attending outpatient department of dermatology of J.L.N. Medical College and associated hospitals Ajmer (RAJ), India. Pregnant and lactating women, children below 5 years, elderly patients more than 60 year, patients not willing to come for follow-up and patients with any serious systemic illness were excluded. Data so collected, were analyzed as per the aims and objectives with the help of appropriate statistical software (primer statistical software version 6).

Results: Efficacy of oral ivermectin therapy was comparable with topical permethrin therapy but more efficacious (statistically significant) than topical gamma benzene hexachloride therapy.

Conclusions: Ivermectin can be a very useful weapon in patients who do not show compliance with topical therapy.

Keywords: Scabies, Ivermectin, Permethrin, Gama benzene hexachloride, Oral, Topical
commercials purify form lindane) malathion and permethrin.

Disease control requires treatment of the affected individual and all people they have been in contact with, but is often hampered by inappropriate or delayed diagnosis, poor treatment compliance and improper use of topical compounds such as permethrin, lindane or benzyl benzoate. Oral ivermectin is an effective and cost-comparable alternative to topical agents in the treatment of scabies infection. It may be particularly useful in the treatment of severely crusted scabies lesions in immune compromised patients or when topical therapy has failed. Oral dosing may be more convenient in institutional outbreaks and in the treatment of mentally impaired patients. The safety of oral ivermectin in pregnant and lactating women and young children has yet to be established.

Hence it was decided to study and compare three antiscabietics-the most commonly used topical antiscabietic-gamma benzene hexachloride, permethrin, and oral ivermectin. The objective of the study was to known the efficacy of oral ivermectin in comparison to commonly used topical antiscabietic drugs gamma benzene hexachloride and permethrin.

**METHODS**

This was a prospective, longitudinal, comparative randomized study conducted in patients attending outpatient department of dermatology of J.L.N. Medical College and associated hospitals Ajmer (Rajasthan), India. 306 patients, in the age group of 5 to 60 years, belonging to both sexes were included in the study after taking consent. The duration of the study was one year; from August 2013 to July 2014. Pregnant and lactating women, children below 5 years, elderly patients more than 60 year, patients not willing to come for follow-up and patients with any serious systemic illness were excluded from the study.

Patients were allocated randomly into three groups i.e. group I, group II and group III. (102 patients in each group).

*Group I*: Patients were given single dose of oral ivermectin 200 µg/kg body weight.

*Group II*: Patients were given topical permethrin 5%.

*Group III*: Patients were given topical gamma benzene hexachloride 1%. Both Permethrin and gamma benzene hexachloride should be applied topically after scrub bath and left overnight.

The patients were followed at 1st week and 6th week. A careful history of the patient was taken. Participants were advised not to use or mix any other treatment, including antihistaminic medicines.

Parameters used to study the efficacy of the regimens:

- Severity of the disease
- Itching

Severity of the disease is measured according to the number of lesions present. It can be graded as:

- Mild (grade-I): <10 lesions
- Moderate (grade-II): 11-49 lesions
- Severe (grade-III): >50 lesions

Severity of itching is evaluated by visual analogues scale (VAS). VAS is defined as a 10 cm line, in which point 0 refers to existence of no pruitus and point 10 refers to the most severe pruritus. According to this scale, we scored pruritus of the patients.

Point 1 to 3: Mild pruritus (grade-I)
Point 4 to 6: Moderate pruritus (grade-II)
Point 7 to 10: Severe pruritus (grade-III)

Pre-structured proforma was used to collect the relevant information (patients data, clinical finding etc) at baseline, 1st week and 6th week of follow-up.

**RESULTS**

Out of 306 patients 7 were dropped out during follow up, 3 from group-I, 2 from group-II & III each, so total 299 patients were evaluated at the end of study. Table 1 shows age & sex incidence of scabies. Most of the patients (35%) belong to the age group of 11-20 years followed by 21-30 years who constituted to 27% of scabies.

Table 2 shows occupational status of patients. Out of 299 patients, majority were students who constituted to 38% (114) followed by daily wagers and agriculturists 23% (69) and 14% (42) respectively.

Table 3 shows family history of scabies and it was positive in 73 % of patients. Table 4 shows that in the present study nocturnal itching was present in 98% of patients.

Table 5 shows location of lesion in scabies patients. In present study interdigital space and flexor aspect of wrist

<p>| Table 1: Age and sex incidence. |
| --- | --- | --- | --- |</p>
<table>
<thead>
<tr>
<th>Age</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-10</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>11-20</td>
<td>63</td>
<td>63</td>
</tr>
<tr>
<td>21-30</td>
<td>49</td>
<td>49</td>
</tr>
<tr>
<td>31-40</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>41-50</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>51-60</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>175</td>
<td>124</td>
</tr>
</tbody>
</table>
were involved in 90.63% of the patients followed by, genitalia, and medial aspect of thigh in 60.20% and 50.16% respectively.

**Table 2: Occupational status of patients.**

<table>
<thead>
<tr>
<th>Occupation</th>
<th>No. of cases</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Students</td>
<td>114</td>
<td>38.12%</td>
</tr>
<tr>
<td>Agriculturists</td>
<td>42</td>
<td>14.05%</td>
</tr>
<tr>
<td>House wives</td>
<td>32</td>
<td>10.7%</td>
</tr>
<tr>
<td>Service class</td>
<td>27</td>
<td>9.03%</td>
</tr>
<tr>
<td>Daily wagers</td>
<td>69</td>
<td>23.08%</td>
</tr>
<tr>
<td>Business man</td>
<td>3</td>
<td>1%</td>
</tr>
<tr>
<td>Others</td>
<td>12</td>
<td>4.01%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>299</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

**Table 3: Family history.**

<table>
<thead>
<tr>
<th>Family history</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td>219</td>
<td>73.24%</td>
</tr>
<tr>
<td>Absent</td>
<td>80</td>
<td>26.76%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>299</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

**Table 4: Nocturnal itching.**

<table>
<thead>
<tr>
<th>Nocturnal itching</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td>292</td>
<td>97.65%</td>
</tr>
<tr>
<td>Absent</td>
<td>7</td>
<td>2.35%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>299</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

Table 6 shows type of lesions. In the present study 181 (90.8%) patients had papular lesions and 172 (86%) had vesicular lesions, 103 (51.8%) had pustules and excoriations were found in 119 (59.5%) of the patients.

**Table 5: Locations of lesion.**

<table>
<thead>
<tr>
<th>Site of lesion</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inter digital space and flexor aspect of wrist</td>
<td>271</td>
<td>90.63%</td>
</tr>
<tr>
<td>Lower abdomen</td>
<td>141</td>
<td>47.15%</td>
</tr>
<tr>
<td>Fore arm</td>
<td>116</td>
<td>38.79%</td>
</tr>
<tr>
<td>Axillary folds</td>
<td>90</td>
<td>30.1%</td>
</tr>
<tr>
<td>Genitalia</td>
<td>180</td>
<td>60.2%</td>
</tr>
<tr>
<td>Thighs (medial aspect)</td>
<td>150</td>
<td>50.16%</td>
</tr>
<tr>
<td>Gluteal region</td>
<td>28</td>
<td>9.36%</td>
</tr>
</tbody>
</table>

**Table 6: Type of lesions.**

<table>
<thead>
<tr>
<th>Type of lesions</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papules</td>
<td>270</td>
<td>90.5%</td>
</tr>
<tr>
<td>Vesicles</td>
<td>257</td>
<td>86%</td>
</tr>
<tr>
<td>Nodules</td>
<td>03</td>
<td>01%</td>
</tr>
<tr>
<td>Pustules</td>
<td>177</td>
<td>59.5%</td>
</tr>
<tr>
<td>Eczematization</td>
<td>110</td>
<td>37%</td>
</tr>
<tr>
<td>Excoriations</td>
<td>153</td>
<td>51.5%</td>
</tr>
<tr>
<td>Crusts</td>
<td>7</td>
<td>2.5%</td>
</tr>
<tr>
<td>Others</td>
<td>22</td>
<td>7.5%</td>
</tr>
</tbody>
</table>

Table 7 shows comparison of results among three Groups at the end of 6 weeks considering severity of itching and severity of the disease as a parameter of efficacy. Efficacy of group-I and group-II were statistically significant as compared with group-III.

**Table 7: Comparison of results of various regimens at the end of 6 weeks.**

<table>
<thead>
<tr>
<th>Regimens</th>
<th>Improved (%)</th>
<th>Not improved (%)</th>
<th>Improved (%)</th>
<th>Not improved (%)</th>
<th>Chi-square test</th>
<th>Difference between groups (p-values)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I- Ivermectin</td>
<td>75 (75.75%)</td>
<td>24 (24.24%)</td>
<td>77 (77.77%)</td>
<td>22 (22.22%)</td>
<td>X²=11.707; P=0.0029 p&lt;.05 (s)</td>
<td>I-II P=0.8666, (ns)</td>
</tr>
<tr>
<td>II- Permethrin</td>
<td>78 (78%)</td>
<td>22 (22%)</td>
<td>77 (77%)</td>
<td>23 (23%)</td>
<td>X²=11.182; P=0.0037 p&lt;.05 (s)</td>
<td>I-III P=0.0106, (s)</td>
</tr>
<tr>
<td>III-Gamabenzenehexachloride</td>
<td>58 (58%)</td>
<td>42 (42%)</td>
<td>59 (59%)</td>
<td>41 (41%)</td>
<td>X²=3.455; P=0.0655, (ns)</td>
<td>II-III P=0.0040, (s)</td>
</tr>
</tbody>
</table>

n- significant, ns- non-significant

**DISCUSSION**

**Age and sex distribution and occupational status**

In present study most of the patients (50%) were in the age group of 6-20 years whereas 27% of the patients were in the age group of 21-30 years. Thus scabies was found to be more common in children and young adults. Similar results were also found in others studies by Sehgal et al, Gulati et al and Nair et al. Incidence of scabies was found more among males as compared to females. Nair et al, Hati et al, Sehgal et al, have also observed male preponderance in their studies. Further, higher incidence of scabies (38.12%) found in students in this study. The higher incidence in children and young adults can attributable to the fact, that intermingling is common among children whereas higher incidence among students is due to multiple causes like playing together in the...
school, living together in hostels and the habit of using
the dresses and linen of the friends, which add to the
transmission of the disease in them. Male preponderance
is attributable to the more chances of exposure.

**Family history**

Family history of scabies was found positive in 73.24% of
patients. Such higher incidence of family history in the
patients of scabies was also reported by Usha et al in their
study on two groups treated with either ivermectin or
permethrin, who had a positive family were 82.5% and
55.6% respectively.5

The higher incidence of family history among the affected
depicts the capacity of scabies to spread among close
contacts and stresses the need for treatment of all the
contacts.

**Nocturnal itching**

Nocturnal itching was present in 97.65% of patients. Nair
et al, found nocturnal itching in 89% of the patients.6
Thus, nocturnal itching may be a helpful information in
making the diagnosis, especially in the absence of
facilities for demonstrating the mite.

**Location of lesions**

In present study interdigital space and flexor aspect of
wrist were involved in 90.63% of the patients followed
by, genitalia and medial aspect of thigh in 60.20% and
50.16% respectively. Lesions on lower abdomen were
present in 47.15% patients. Desai et al have observed the
involvement of hands and wrists in 84.8% of their cases.7
Thus, location of lesion can be a useful clinical indicator.

However in the present study involvement of genitalia
was seen in 60.20% whereas Desai et al and Hati et al,
observed genital involvement only in 36% and 23.8% of
cases respectively.7,4 Regarding the involvement of other
sites like axillae and buttocks, the different authors have
observed variable percentage of involvement in their
studies.

**Type of lesions**

In the present study 90.8% patients had papular lesions
and 86% had vesicular lesions. Jackson et al, found
papular lesions most commonly in scabies patients. Usha
et al, found that 25% of patients out 40 patients treated
with ivermectin had secondary infection.8,5 The secondary
infection (pustules) in this study (59.5%) was more
compared to (25%) in Usha et al study.5

This may be because of the low education level,
overcrowding, unhygienic condition, lack of awareness in
our patients compared to Kerala were the study was
conducted by Usha et al.5

**Response to treatment in various regimens**

**Oral ivermectin (200 µg/kg body weight, single dose)**

Oral ivermectin given as single dose (200µg/kg body
weight) in patients of scabies. Out of 99 patients
considering the itching as the parameter, 52 (52.52 %)
patients improved at 2 weeks and 23 (23.23%) between
2nd-6th week. Total number of patients showing after
complete subsidence at 6th week was 75 (75.75%).

Similarly considering severity of lesion as the parameter
in 99 patients, improvement was seen in 63 (63.63%) and
14 (14.14%) at 2nd and between 2nd-6th week. Total
number of patients who showed improvement was
77 (77.77%).

Usha et al, found that a single dose of ivermectin
provided a cure rate of 70%, which increased to 95% with
2 doses at a 2 week interval. Meinking et al, reported
100% clearance with single oral dose of ivermectin in 11
patients with uncomplicated scabies.5,9 Chouela et al,
found the cure rate of scabies at 15th day, after treatment
with ivermectin single dose of (150 – 200 µg/kg) to be
74%.10

**Topical permethrin 5% lotion (single application)**

Out of 100 patients treated with 5% permethrin lotion
cure was seen in 56% and 22% at 2nd week and between
2nd-6th weeks respectively .Total number of patients
cured at 6th week was 78%.

Considerably the severity of lesion, number of patients
cured was 62% and 15% at 2nd week and between 2nd-
6th weeks respectively. Total number of patients cured at
6th week was 77%.

Zargari et al, and Taplin et al, have found a cure rate of
84.6% and 43% respectively after 2 weeks of therapy.11,12
Similarly Hegary et al and Usha et al found permethrin to
be effective as a single application with cure rate of
84.9% and 97.8% respectively.13,5

**Topical GBHC 1% lotion (single application)**

Out of 100 patients in the present study with itching as the
parameter, improvement with GBHC 1% lotion was
seen in 39% and 19% of the patients at 2nd week and between
2nd-6th weeks respectively. Total improvement was seen
in 58% patients.

Considering severity of lesion as the parameter,
 improvement was seen in 49% and 10% of patients at 2nd
week and between 2nd and 6th week respectively. Total
improvement was seen in 59 % patients. Taplin et al,
Zargari M et al, Chouela et al, have found 65%, 48.9%,
44.44%, 54% cure rate respectively with 1% lindane
lotion after 1 month.10,12,14
Comparison of statistical significance among three groups

Difference in efficacy of group I (ivermectin) therapy was statistically non-significant with group II (permethrin) but statistically significant with group III (gama benzene hexachloride). This shows that efficacy of group I therapy was comparable to group II therapy but more efficacious than group III therapy. Group II therapy was more efficacious than group III because difference in efficacy was statistically significant. Thus the finding of present study has statistical validation between groups.

Although topical agents carried certain drawbacks, present study reported that single application of permethrin 5% gave maximum response when severity of itching and severity of lesion were taken as parameters to compare efficacy of different groups thus making it the most effective treatment and therefore suitable to be the treatment of choice.

Response to single oral dose of ivermectin 200 μg/kg body weight was slightly low when compared to topical permethrin but higher when compared to response obtained with topical GBHC. Though the results obtained with single oral dose of ivermectin (200 μg/kg body weight) in patients belonging to group I were slightly low compared to permethrin, patient acceptance was very good especially among students living in hostels, where inadequate facilities for bathing and taking a good scrub bath were the major hurdle in topical application.

Despite the need for further exploration, oral ivermectin could be a viable alternative for management of scabies especially where compliance to topical scabicides is improbable or impractical.

A significant reduction in disease burden is possible only when along with appropriate scabicides, treatment of all contacts and clothings are done simultaneously and the underlying environmental and social conditions that promote infectious skin diseases are addressed. Improvement in literacy and economic status along with awareness about personal hygiene can definitely bring down the prevalence of this disease.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES